Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MPLT
SELLMapLight Therapeutics, Inc. · Healthcare · United States · $1.7B · Avg Vol: $20M/d
COMPANY DESCRIPTION
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing novel therapeutics for central nervous system (CNS) disorders, with a primary focus on psychiatric and neurological conditions. The company employs a proprietary drug discovery platform to identify and advance differentiated small molecule candidates that target specific neuroreceptor pathways, aiming to address significant unmet medical needs with potential first-in-class treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | — | — | — | 18.2M | — |
| EPS | — | — | -2.96 | -18.56 | — | -4.19 | -5.09 | -3.81 | — |
| Shares | — | — | — | 44.0M | — | 42.6M | — | — | — |
| Debt | — | — | — | 5.8M | — | 5.6M | — | — | — |
| Equity | 20.9M | 71.3M | 115.2M | 458.4M | 180.0% | — | — | — | — |
| Op CF | — | — | — | -138.1M | — | -163.8M | — | — | — |
| Inv CF | — | — | — | -323.2M | — | — | — | — | — |
| Fin CF | — | — | — | 469.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MPLT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc.(you) | $1.7B | 25 | SELL |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.9B | 25 | SELL |
| STOK | Stoke Therapeutics, Inc. | $1.8B | 26 | SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
| TYRA | Tyra Biosciences, Inc. | $1.8B | 20 | SELL |
| MNKD | MannKind Corporation | $1.3B | 23 | SELL |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 30 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 18 | STRONG SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 28 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%